Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Some cancers may become resistant to chemotherapy drugs.
Combining PSC 833 with chemotherapy may reduce resistance to the drugs and allow the cancer
cells to be killed. Interleukin-2 may stimulate a person's white blood cells to kill leukemia
cells.
PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy plus PSC 833
followed by additional chemotherapy or peripheral stem cell transplantation and interleukin-2
in treating patients with untreated acute myelogenous leukemia.